MEDICAL DIRECTOR & CHIEF OF URO-GENITO ONCOLOGY
Rajiv Gandhi Cancer Institute & Research Centre, India
Dr. Sudhir Rawal
Medical Director & Chief of Uro-Genito Oncology
Rajiv Gandhi Cancer Institute & Research Centre, Delhi
Dr. Sudhir Rawal is a leading figure in Genito-urinary Oncology with over 36 years of experience in cancer care and surgical innovation. Currently serving as the Medical Director and Chief of Uro-Genito Oncology at Rajiv Gandhi Cancer Institute, Delhi, he has performed over 35,000 surgeries, including 6,000+ robotic procedures, and pioneered advanced treatments for cancers of the bladder, kidney, prostate, and testis.
He is credited with establishing India’s first dedicated Genito-Urinary Surgical Oncology department and performing the country’s first telesurgery in oncology. Dr. Rawal played a key role in developing India’s indigenous surgical robot, SSI Mantra, offering a cost-effective alternative to imported systems. His surgical innovations include the internationally recognized "Pitcher's Pot" ileal neobladder.
A respected academic, Dr. Rawal has authored numerous peer-reviewed papers and serves on the editorial boards of World Journal of Urology and the British Journal of Urology. He has trained more than 20 uro-oncology specialists and actively leads clinical research as Chairman of the hospital’s Scientific Committee.
Recognized with awards such as the Lifetime Achievement in Robotic Surgery (2019) and Times Best Doctor Award, Dr. Rawal is also committed to philanthropic care. His institute provides free cancer treatment to underprivileged patients and home-based palliative services through partnerships like Ganga Prem Hospice.
Dr. Rawal’s career is marked by excellence in surgery, innovation in healthcare technology, and a deep commitment to accessible cancer care.
SYMP-06: Focal treatment in prostate cancer – Indications and Options
Wednesday, October 29, 2025
11:03 - 11:10 GMT+0
SYMP-10: Session II - Point of Technique
Wednesday, October 29, 2025
12:15 GMT+0
MC-04: Master Class: Contemporary Management of Upper Tract Urothelial Cancer
Friday, October 31, 2025
15:15 - 16:45 GMT+0